title: [Platelets activation in depending on glycaemic control in diabetes type 2].
abstract: Both metabolic and heamodynamic disorders accompany diabetes. Inadequate control of glycaemia, glication proteins and oxidative stress causes chronic thromboembolic and atherothrombosis complications. Disorders which are observed in diabetes induce intravascular platelets activation and changes with platelets' morphologic parameters. It is interesting if this process depends on glycaemic control diabetes? The aim of our study was to investigate in patients with type 2 diabetes the level of beta-thromboglobulin as the platelets activation marker and platelet count (PLT), mean platelet volume (MPV), which depend on diabetes control.
  
  
  METHODS
  The study group included 58 patients with type 2 diabetes (middle ages was 58) with long-term anamnesis and treated only with insulin. The control group was composed by 36 healthy people (middle ages was 54). The study group was categorized into two subgroups, in depending on percent of glycosylated haemoglobin (HbA1c) which is a marker of diabetes control: B1--HbA1c < 7,5%--(13 people), B2--HbA1c > or = 7,5%--(45 people). Identical set research (beta-TG, PLT MPV and HbA1c) were carried out in both study group and the control group. Blood samples were collected from elbow vein, with no staza use and were put to test- tubes with disodium versenate (EDTA-K2) and to vacuum test- tubes Vacutainer with anticoagulant CTAD.
  
  
  RESULTS
  We didn't observe significantly important differences in the research parameters: B-TG, MPV and PLT between subgroups with good diabetes control and worse diabetes control. The level of beta-thromboglobulin and the mean platelet volume was significantly important higher in the study group than in the control subjects. However, PLT--platelet count, in the blood collected from patients with type 2 diabetes was slightly lower than in the control group.
  
  
  CONCLUSIONS
  Increased activation of platelets in patients with type 2 diabetes does not depend on glycaemic control diabetes.
authors.affiliation: Uniwersytet Medyczny w Białymstoku, Zakład Laboratoryjnej Diagnostyki Klinicznej.
authors.forename: Joanna
authors.initials: J
authors.lastname: Wojszel
authors.forename: Jolanta
authors.initials: J
authors.lastname: Czyzewska
authors.forename: Violetta
authors.initials: V
authors.lastname: Dymicka-Piekarska
authors.forename: Joanna
authors.initials: J
authors.lastname: Matowicka-Karna
authors.forename: Iwona
authors.initials: I
authors.lastname: Jakubowska
authors.forename: Halina
authors.initials: H
authors.lastname: Kemona
mesh_terms: D000328:Adult; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D038321:Glycemic Index; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015539:Platelet Activation; D010976:Platelet Count; D001620:beta-Thromboglobulin / Q000378:metabolism
chemical_list: D006442:Glycated Hemoglobin; D007328:Insulin; D001620:beta-Thromboglobulin